Impact of Adjuvant Ocular Interventions on the Quality of Life of Patients with Uveal Melanoma after Proton Beam Therapy.

Pub Date : 2022-06-01 DOI:10.1159/000520524
Johannes Gollrad, Christopher Rabsahl, Antonia M Joussen, Andrea Stroux, Volker Budach, Dirk Böhmer, Alexander Böker
{"title":"Impact of Adjuvant Ocular Interventions on the Quality of Life of Patients with Uveal Melanoma after Proton Beam Therapy.","authors":"Johannes Gollrad,&nbsp;Christopher Rabsahl,&nbsp;Antonia M Joussen,&nbsp;Andrea Stroux,&nbsp;Volker Budach,&nbsp;Dirk Böhmer,&nbsp;Alexander Böker","doi":"10.1159/000520524","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Proton beam therapy is an established primary treatment for patients with nonmetastasized uveal melanoma. Adjuvant local interventions, like intravitreal injections or surgery, were shown to improve long-term eye preservation; however, their impact on the patient's quality of life (QOL) remains unknown.</p><p><strong>Methods: </strong>In a post-radiotherapeutic follow-up, we prospectively collected data on QOL, visual acuity, and interventional adjuvant procedures. QOL was measured with QOL-C30 questionnaire and quality of life questionnaire OPT30 at baseline, and at 3 and 12 months after proton therapy. Patients were grouped by the type of adjuvant treatment. The impact on QOL was analyzed by comparing changes in the mean score values and visual acuity for different interventional subgroups, with generalized linear mixed models and Wilcoxon signed-rank tests.</p><p><strong>Results: </strong>We received 108 (100%) and 95 (88.0%) questionnaires at 3 and 12 months post-therapy, respectively. Adjuvant interventions included observation (<i>n</i> = 61, 56.5%), intravitreal injections (<i>n</i> = 17, 15.7%), and an intraocular surgical procedure (<i>n</i> = 30, 27.8%). In the latter group, several QOL items significantly declined after the 3-month adjuvant interval, but they partially recovered at the 12-month follow-up. In all adjuvant-intervention groups, global QOL scores returned to baseline levels at 12 months.</p><p><strong>Conclusion: </strong>Posttreatment adjuvant interventions had no long-lasting effects on QOL in patients with uveal melanoma.</p>","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218619/pdf/oop-0008-0110.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000520524","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Proton beam therapy is an established primary treatment for patients with nonmetastasized uveal melanoma. Adjuvant local interventions, like intravitreal injections or surgery, were shown to improve long-term eye preservation; however, their impact on the patient's quality of life (QOL) remains unknown.

Methods: In a post-radiotherapeutic follow-up, we prospectively collected data on QOL, visual acuity, and interventional adjuvant procedures. QOL was measured with QOL-C30 questionnaire and quality of life questionnaire OPT30 at baseline, and at 3 and 12 months after proton therapy. Patients were grouped by the type of adjuvant treatment. The impact on QOL was analyzed by comparing changes in the mean score values and visual acuity for different interventional subgroups, with generalized linear mixed models and Wilcoxon signed-rank tests.

Results: We received 108 (100%) and 95 (88.0%) questionnaires at 3 and 12 months post-therapy, respectively. Adjuvant interventions included observation (n = 61, 56.5%), intravitreal injections (n = 17, 15.7%), and an intraocular surgical procedure (n = 30, 27.8%). In the latter group, several QOL items significantly declined after the 3-month adjuvant interval, but they partially recovered at the 12-month follow-up. In all adjuvant-intervention groups, global QOL scores returned to baseline levels at 12 months.

Conclusion: Posttreatment adjuvant interventions had no long-lasting effects on QOL in patients with uveal melanoma.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
辅助眼部干预对质子束治疗后葡萄膜黑色素瘤患者生活质量的影响。
质子束治疗是非转移性葡萄膜黑色素瘤的主要治疗方法。辅助的局部干预,如玻璃体内注射或手术,可以改善长期的眼睛保护;然而,它们对患者生活质量(QOL)的影响尚不清楚。方法:在放疗后随访中,我们前瞻性地收集了生活质量、视力和介入性辅助手术的数据。在基线、质子治疗后3个月和12个月分别用QOL- c30问卷和生活质量问卷OPT30测量患者的生活质量。患者按辅助治疗方式分组。采用广义线性混合模型和Wilcoxon符号秩检验,比较不同介入亚组的平均评分值和视力的变化,分析对生活质量的影响。结果:治疗后3个月和12个月,我们分别收到108份(100%)和95份(88.0%)问卷。辅助干预措施包括观察(n = 61, 56.5%)、玻璃体内注射(n = 17, 15.7%)和眼内手术(n = 30, 27.8%)。后一组在辅助治疗间隔3个月后,多项生活质量指标明显下降,但在随访12个月时部分恢复。在所有辅助干预组中,总体生活质量评分在12个月时恢复到基线水平。结论:治疗后辅助干预对葡萄膜黑色素瘤患者的生活质量无长期影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1